BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal

Reuters02-11

Feb 11 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:

EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FOR SEVERAL SIRNA ASSETS
TO RECEIVE $60 MILLION UPFRONT PAYMENT, UP TO $4.4 BILLION TOTAL
LICENSING DEAL FOR 6 PRE-CLINICAL SIRNA PROGRAMS FOR TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Further company coverage: 6938.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610933517?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 18:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610933517","market":"us","top_or_hot":-1,"title":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal</title></head><body><p><span>Feb 11 (Reuters)</span><span> - </span>Suzhou Ribo Life Science Co Ltd <span>6938.HK</span>:</p><ul><li><p>EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FOR SEVERAL SIRNA ASSETS</p></li><li><p>TO RECEIVE $60 MILLION UPFRONT PAYMENT, UP TO $4.4 BILLION TOTAL</p></li><li><p>LICENSING DEAL FOR 6 PRE-CLINICAL SIRNA PROGRAMS FOR TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS</p></li></ul><p>Further company coverage: <span>6938.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 18:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal</title></head><body><p><span>Feb 11 (Reuters)</span><span> - </span>Suzhou Ribo Life Science Co Ltd <span>6938.HK</span>:</p><ul><li><p>EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FOR SEVERAL SIRNA ASSETS</p></li><li><p>TO RECEIVE $60 MILLION UPFRONT PAYMENT, UP TO $4.4 BILLION TOTAL</p></li><li><p>LICENSING DEAL FOR 6 PRE-CLINICAL SIRNA PROGRAMS FOR TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS</p></li></ul><p>Further company coverage: <span>6938.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:1","article_id":"2610933517","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610933517","pubTimestamp":1770804556,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With MadrigalFeb 11 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","MDGL":"Madrigal Pharmaceuticals, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","06938":"瑞博生物-B","BK4139":"生物科技"},"translate_title":"简介-苏州日博生命科学与Madrigal签署全球独家授权协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":0.9,"06938":0.9},"content_text":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With MadrigalFeb 11 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FOR SEVERAL SIRNA ASSETSTO RECEIVE $60 MILLION UPFRONT PAYMENT, UP TO $4.4 BILLION TOTALLICENSING DEAL FOR 6 PRE-CLINICAL SIRNA PROGRAMS FOR TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITISFurther company coverage: 6938.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610933517","isCrawlerRequest":true}